Altered Circulating Leptin, hGH, and IGF-I in Prediabetes and Screening-Diagnosed T2DM Unrelated to Metabolic Syndrome in Women Post Gestational Diabetes.


Journal

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
ISSN: 1439-4286
Titre abrégé: Horm Metab Res
Pays: Germany
ID NLM: 0177722

Informations de publication

Date de publication:
Sep 2022
Historique:
pubmed: 14 5 2022
medline: 11 9 2022
entrez: 13 5 2022
Statut: ppublish

Résumé

Recently, we proposed two pathophysiologic subtypes of type 2 diabetes mellitus (T2DM), one related and one unrelated to metabolic syndrome. To begin to understand the pathophysiology of the subtype unrelated to metabolic syndrome, we now measured selected hormones and signaling molecules in affected individuals. In this cross-sectional analysis, we examined 138 women out of the monocenter, post gestational diabetes study PPSDiab. Of these women, 73 had prediabetes or screening-diagnosed T2DM, 40 related to metabolic syndrome and 33 unrelated. The remaining 65 women were normoglycemic controls. Our analysis included medical history, anthropometrics, oral glucose tolerance testing, laboratory chemistry, and cardiopulmonary exercise testing. In addition, plasma proinsulin/insulin ratio, growth hormone (hGH) nadir during oral glucose tolerance testing, Insulin-like Growth Factor I (IGF-I), Leptin, Resistin, Adiponectin, Fetuin-a, FGF21, and myostatin were measured. Compared to controls, women with prediabetes or screening-diagnosed T2DM unrelated to metabolic syndrome depicted higher plasma Leptin [10.47(6.6-14.57) vs. 5.52(3.15-10.02); p<0.0001] and IGF-I [193.01(171.00-213.30) vs. 167.97(138.77-200.64); p=0.0008], as well as a lower hGH nadir [0.07(0.05-0.15) vs. 0.14(0.08-0.22; p<0.0001]. These differences were independent of body adiposity. Women with prediabetes or T2DM related to metabolic syndrome, in comparison to controls, displayed elevated Leptin, Fetuin-a, and FGF21, as well as reduced Adiponectin and hGH nadir. Based on our study, altered Leptin and hGH/IGF-I signaling could potentially contribute to the pathophysiology of prediabetes and T2DM unrelated to metabolic syndrome. Further mechanistic investigations of these signaling pathways in the context of lean T2DM are necessary to test causal relationships.

Identifiants

pubmed: 35556239
doi: 10.1055/a-1850-5392
doi:

Substances chimiques

Adiponectin 0
Leptin 0
alpha-2-HS-Glycoprotein 0
Insulin-Like Growth Factor I 67763-96-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

613-619

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Stefanie Kern-Matschilles (S)

Diabetes Research Group, LMU Klinikum München, Medizinische Klinik und Poliklinik IV, München, Germany.
Clinical Cooperation Group Type 2 Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.
(DZD), German Center for Diabetes Research, Neuherberg, Germany.

Christina Gar (C)

Diabetes Research Group, LMU Klinikum München, Medizinische Klinik und Poliklinik IV, München, Germany.
Clinical Cooperation Group Type 2 Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.
(DZD), German Center for Diabetes Research, Neuherberg, Germany.

Katharina Schilbach (K)

Endocrine Research Unit, LMU Klinikum München, Medizinische Klinik IV, München, Germany.

Stefanie Julia Haschka (SJ)

Diabetes Research Group, LMU Klinikum München, Medizinische Klinik und Poliklinik IV, München, Germany.
Clinical Cooperation Group Type 2 Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.
(DZD), German Center for Diabetes Research, Neuherberg, Germany.

Barbara Rauch (B)

Diabetes Research Group, LMU Klinikum München, Medizinische Klinik und Poliklinik IV, München, Germany.
Clinical Cooperation Group Type 2 Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.
(DZD), German Center for Diabetes Research, Neuherberg, Germany.

Cornelia Then (C)

Diabetes Research Group, LMU Klinikum München, Medizinische Klinik und Poliklinik IV, München, Germany.
Clinical Cooperation Group Type 2 Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.
(DZD), German Center for Diabetes Research, Neuherberg, Germany.

Jochen Seissler (J)

Diabetes Research Group, LMU Klinikum München, Medizinische Klinik und Poliklinik IV, München, Germany.
Clinical Cooperation Group Type 2 Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.
(DZD), German Center for Diabetes Research, Neuherberg, Germany.

Martin Bidlingmaier (M)

Endocrine Research Unit, LMU Klinikum München, Medizinische Klinik IV, München, Germany.

Andreas Lechner (A)

Clinical Research Group, LMU Klinikum München, Medizinische Klinik und Poliklinik 4, München, Germany.
Clinical Cooperation Group Type 2 Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.
(DZD), German Center for Diabetes Research, Neuherberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH